Latest News
AIFA Opens the Door: Patients Now Have a Seat at the HTA Table
Italy's medicines agency AIFA has taken a significant step forward in how health technology assessment bodies engage with stakeholders—and it's excellent news for patients with [...]
The first JCA dossiers could arrive mid-2026; how will they impact market access?
The Joint Clinical Assessment (JCA) framework represents a significant shift in how pharmaceutical products are evaluated across the EU. It aims to create a unified [...]
Shionogi’s Acquisition of Mitsubishi Tanabe Pharma’s Radicava Business
Yesterday afternoon, I listened with interest to a presentation on Pharma’s Deal Review: M&A Dynamics Ahead of JPM 2026 delivered by Marc de Garidel, Eric [...]
Changes to NICE’s cost-effectiveness thresholds confirmed
This change aims to enhance the operating environment for pharmaceutical companies in the UK, supporting innovation and the sector’s growth. Dr. Samantha Roberts, CEO of [...]
Landmark UK-US trade deal
On Wednesday, October 1, 2025, the UK-US landmark deal was announced on the government website. Tens of thousands of NHS patients will benefit from a [...]
Navigating the challenges of Clinical Trials in Rare Disease
Designing clinical trials for rare diseases requires balancing scientific rigour with practical realities. A key challenge – the frequent use of a 2:1 randomisation ratio. [...]
Companies granted third extension to VPAG 2026
The ABPI and the government have extended the deadline for companies to announce their exit from the 2024 voluntary scheme for branded medicine pricing, access, [...]
Who will truly benefit? MFN deals
AstraZeneca’s Agreement with the U.S. Government AstraZeneca announced a landmark agreement with the Trump administration to cut American prescription drug prices on October 10, 2025. [...]
True synergistic combination therapy
Over the last few weeks, I’ve noticed several online discussions about Combination Therapies. Having supported a client a few years back in developing a strategic [...]
Latest News
AIFA Opens the Door: Patients Now Have a Seat at the HTA Table
Italy's medicines agency AIFA has taken a significant step forward in how health technology assessment bodies engage with stakeholders—and it's excellent news for patients with [...]
The first JCA dossiers could arrive mid-2026; how will they impact market access?
The Joint Clinical Assessment (JCA) framework represents a significant shift in how pharmaceutical products are evaluated across the EU. It aims to create a unified [...]
Shionogi’s Acquisition of Mitsubishi Tanabe Pharma’s Radicava Business
Yesterday afternoon, I listened with interest to a presentation on Pharma’s Deal Review: M&A Dynamics Ahead of JPM 2026 delivered by Marc de Garidel, Eric [...]
Changes to NICE’s cost-effectiveness thresholds confirmed
This change aims to enhance the operating environment for pharmaceutical companies in the UK, supporting innovation and the sector’s growth. Dr. Samantha Roberts, CEO of [...]
Landmark UK-US trade deal
On Wednesday, October 1, 2025, the UK-US landmark deal was announced on the government website. Tens of thousands of NHS patients will benefit from a [...]
Navigating the challenges of Clinical Trials in Rare Disease
Designing clinical trials for rare diseases requires balancing scientific rigour with practical realities. A key challenge – the frequent use of a 2:1 randomisation ratio. [...]
